trending Market Intelligence /marketintelligence/en/news-insights/trending/uCteDrNbBgaUqkl9-otGGQ2 content esgSubNav
In This List

Genentech's breast cancer treatment only slightly better than existing therapy

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Genentech's breast cancer treatment only slightly better than existing therapy

Genentech Inc. reported positive results from the phase 3 trial evaluating Perjeta, Herceptin and chemotherapy in patients with HER2-positive early breast cancer.

The Roche Holding Ltd. unit said the combination treatment significantly reduced the risk of breast cancer recurrence or death by 19% in HER2-positive early breast cancer patients, compared to Herceptin and chemotherapy alone.

However, the combined treatment showed only a slight benefit over the existing standard of care. At three years, 94.1% of patients treated with the Perjeta-based regimen did not have their breast cancer return, compared with 93.2% treated with Herceptin and chemotherapy.

Perjeta and Herceptin are both developed by Genentech.